Heren Health

Explore the latest insights on Heren Health and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Heren Health’s developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Company Drug

Pfizer’s Oral Ritlecitinib Meets Primary Endpoints in Phase III Nonsegmental Vitiligo Trials – Largest‑Ever Oral Systemic Program Clears Path for Global Filings

Pfizer Inc. (NYSE: PFE) announced that ritlecitinib (brand name Litfulo), an oral kinase inhibitor, met the primary endpoints in two Phase III trials in nonsegmental vitiligo, with data presented at…

October 3, 2026

Qyuns Therapeutics’ Oturkibart Delivers Late‑Breaking Phase III Data in Prurigo Nodularis at EADV 2026 – IL‑4Rα Antibody Beats Placebo on Itch and Lesion Clearance

October 2, 2026

Abogen Biosciences Strikes Licensing and Option Deal with Novartis for ABO2203 – Up to $7.2 Billion to Advance the First mRNA‑Encoded T‑Cell Engager in Autoimmune Disease

October 2, 2026

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.

Explore Now

Company Deals

Topchoice Medical to Acquire 19% Stake in Heren Health for $72.2M

January 16, 2025